BioLight’s Eye-D to be featured at Boston conference

BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) Eye-D platform insert will be presented at the 5thAnnual Partnership Opportunities in Drug Delivery conference in Boston on Oct. 5.

The Eye-D is BioLight’s platform insert for controlled release of ophthalmic medications and is designed to address the known poor compliance of eye drops administration.

The first Eye-D indication, VS-101, contains the market leading glaucoma drug, latanoprost.

Utilizing a simple in-office procedure, VS-101 is intended to release prostaglandin analog drug in a controlled manner over time, providing 100% patient compliance to drug therapy.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.